Table 2 Preoperative clinicopathological factors and risk of lymph node metastasis in patients with endometrial cancer.
Category | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
OR | (95%CI) | P value | OR | (95%CI) | P value | |
(A) NCCH cohort (n = 125) | ||||||
Biopsy histology (HGEC / LGEC) | 1.49 | (0.73–3.07) | 0.28 | – | – | – |
MRI | ||||||
Myometrial invasion (≥ 50% / < 50%) | 4.60 | (2.12–10.0) | < 0.01 | 3.96* | (1.60–9.78) | < 0.01 |
Tumor diameter (high / low)1 | 4.04 | (1.89–8.64) | < 0.01 | 1.97* | (0.80–4.82) | 0.14 |
Enlarged lymph nodes (positive / negative) | 5.22 | (1.98–13.7) | < 0.01 | 4.45* | (1.41–14.0) | 0.01 |
Serum CA125 level (high / low)2 | 8.13 | (3.34–19.7) | < 0.01 | 5.70* | (2.09–15.5) | < 0.01 |
(B) SUH cohort (n = 129) | ||||||
Biopsy histology (HGEC / LGEC) | 1.03 | (0.41–2.60) | 0.95 | – | – | – |
MRI | ||||||
Myometrial invasion (≥ 50% / < 50%) | 4.04 | (1.68–9.67) | < 0.01 | 2.42* | (0.89–6.61) | 0.08 |
Tumor diameter (high / low)1 | 2.56 | (1.09–5.99) | 0.03 | 1.42* | (0.51–3.95) | 0.50 |
Enlarged lymph nodes (positive / negative) | 5.22 | (1.98–13.7) | 0.04 | 2.26* | (0.42–12.2) | 0.34 |
Serum CA125 level (high / low)2 | 13.4 | (5.00–35.9) | < 0.01 | 9.40* | (3.31–26.7) | < 0.01 |
(C) Combined NCCH cohort and SUH cohort (n = 254) | ||||||
Biopsy histology (HGEC / LGEC) | 1.48 | (0.86–2.56) | 0.16 | – | – | – |
MRI | ||||||
Myometrial invasion (≥ 50% / < 50%) | 4.55 | (2.57–8.06) | < 0.01 | 3.28** | (1.69–6.36) | < 0.01 |
Tumor diameter (high / low)1 | 3.29 | (1.89–5.74) | < 0.01 | 1.73** | (0.89–3.37) | 0.11 |
Enlarged lymph nodes (positive / negative) | 5.45 | (2.55–11.7) | < 0.01 | 3.59** | (1.40–9.17) | < 0.01 |
Serum CA125 level (high / low)2 | 8.24 | (4.50–15.1) | < 0.01 | 6.98** | (3.43–14.2) | < 0.01 |
